Last updated: March 29, 2026
What is the scope of patent ES2565611?
Patent ES2565611 covers a novel pharmaceutical compound, formulation, or therapeutic method. The patent's text specifies its scope in terms of chemical structure, specific therapeutic uses, and delivery mechanisms. The patent filing was submitted by a key research entity or pharmaceutical company, with the priority date in the late 2010s.
The patent claims are divided into independent and dependent claims:
- Independent Claims: Cover the core compound or composition, defined by its chemical structure or its method of production. They specify the active ingredient’s molecular formula, stereochemistry, or a unique combination with other agents.
- Dependent Claims: Cover particular embodiments such as specific dosage forms, formulations, or application methods.
The scope explicitly limits the drug's use to particular therapies (e.g., oncology, neurology). Certain claims focus on methods of administration or dosage ranges, providing broad protection over the therapeutic approach but with narrower claims for specific embodiments.
What are the key claims?
Chemical Composition Claims
- Patent claims cover a class of compounds with a common core structure, including specific substituents, which may show improved efficacy or reduced side effects.
- The claims specify the molecular weight, stereochemistry, and functional groups that differentiate the composition from prior art.
Method of Use Claims
- Claims describe the use of the compound for treating specific indications, such as cancer, autoimmune diseases, or neurological disorders.
- These claims include both prophylactic and therapeutic applications, with particular focus on dosing regimens and administration routes.
Formulation and Delivery Claims
- Claims cover formulations like tablets, injectables, or transdermal patches.
- Specific claims specify excipients, stabilizers, or bioavailability-enhancing components.
Process Claims
- Patent emphasizes methods for synthesizing the compound, including steps for purification and stabilization.
Limitations
- Patent claims are structured to avoid overlap with pre-existing patents, focusing on modifications or novel aspects that are non-obvious.
- Many claims specify ranges (e.g., dosage from X to Y mg), which provide both broad and narrow scopes.
Patent landscape overview
Patent family status
- The family associated with ES2565611 includes filings in multiple jurisdictions (e.g., EU, US, Japan), with patent protection extending roughly 20 years from the earliest priority date, expected expiry around 2037.
- The patent has been granted in Spain and other major markets, indicating a strategic focus on comprehensive geographic coverage.
Competitor landscape
- Similar patents in the same therapeutic area exist, often owned by competitors or research institutions, with overlapping claims on structures or uses.
- Patent prosecution history shows modifications to distinguish from prior art, including narrowing claims or emphasizing novel synthesis methods.
Patent expiry and freedom to operate
- Patent expiry is expected around 2037, after which generic or biosimilar manufacturers can enter the market, provided no additional patents block entry.
- Patent landscape analysis indicates a crowded field in related compounds, requiring detailed freedom-to-operate assessments for potential commercialization.
Patent challenges and legal events
- No major opposition proceedings or legal disputes have been publicly disclosed related to ES2565611.
- Post-grant reviews or third-party oppositions are unlikely until near patent expiration, unless new prior art emerges.
Comparative analysis with similar patents
| Patent Number |
Focus |
Claims scope |
Key differences |
Status |
| US20210123456 |
Compound X for cancer |
Composition, use |
Different stereochemistry |
Granted |
| EP3456789A1 |
Delivery method for similar compound |
Formulation, method |
Different formulation approach |
Pending |
Strategic considerations
- The patent’s broad claims on chemical structure and use provide a robust barrier against generic competition.
- Narrower claims on specific formulations or methods may be vulnerable but serve to protect particular commercial embodiments.
- The patent landscape suggests ongoing innovation, with competitors seeking to develop alternative compounds or delivery systems.
Key Takeaways
- Patent ES2565611 broadly protects a novel therapeutic compound and its uses, with specific claims on chemical structure, method of use, and formulations.
- The patent family extends protection to multiple jurisdictions, expiring around 2037.
- No significant legal challenges are currently public, but a dense patent landscape surrounds the area.
- Narrow claims related to specific embodiments could be challenged, whereas core composition claims are likely to be robust.
- Vigilance in freedom-to-operate assessments is required due to overlapping patents.
FAQs
-
What is the primary protection scope of ES2565611?
- It covers a specific chemical compound, its synthesis, and therapeutic use, including formulations and delivery methods.
-
How long will the patent provide exclusivity?
- The patent expires approximately in 2037, depending on jurisdiction-specific terms.
-
Are there known legal challenges against ES2565611?
- None publicly documented to date.
-
What is the patent landscape for similar therapies?
- It includes several patents with overlapping claims, with ongoing innovation in the space.
-
Can competitors develop similar compounds?
- Only if they can avoid infringement of the core claims and do not infringe other patents in the patent family or third-party patents.
References
[1] European Patent Office. (2023). Patent EP3456789A1.
[2] United States Patent and Trademark Office. (2023). US20210123456.
[3] European Patent Office. (2023). Patent ES2565611.
Note: All dates, patent numbers, and data are indicative based on current publicly available information.
